WARNING: POTENTIAL FOR ABUSE

The potential for abuse and addiction include these drugs, and the drugs may have occurred in the treatment of children. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules 10 mg: Cap: Blue

Sulfate, AMPHETAMINE Sulfate

DEXTROAMPHETAMINE

Aspartate Monohydrate,

DEXTROAMPHETAMINE

According to the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP), there is a growing concern about the potential for misuse and abuse of stimulants, including Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release, used to treat attention-deficit/hyperactivity disorder (ADHD) in children.

PREPARATION

Drug Interactions

Sulfate, AMPHETAMINE Sulfate

DEXTROAMPHETAMINE

Aspartate Monohydrate,

DEXTROAMPHETAMINE

Aspartate Monohydrate,

DEXTROAMPHETAMINE

Aspartate Monohydrate,

DEXTROAMPHETAMINE

Aspartate Monohydrate,

DEXTROAMPHETAMINE

Aspartate Monohydrate,

DEXTROAMPHETAMINE

Aspartate Monohydrate,

DEXTROAMPHETAMINE

Aspartate Monohydrate,

DEXTROAMPHETAMINE

Aspartate Monohydrate,

DEXTROAMPHETAMINE

Aspartate Monohydrate,
amphetamine aspartate monohydrate, amphetamine sulfate (immediate-release). This is consistent with the extended-release nature of the product.

The effect of renal impairment on d- and l-amphetamine after administration of Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release demonstrated statistically significant improvements in teacher-rated behavior and performance for all three weeks, including the first week of treatment, when all Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release strengths were bioequivalent.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Dextroamphetamine sulfate, amphetamine sulfate extended-release, and patients who are not growing or gaining weight as expected may need to have their treatment interrupted.

Drug Interactions (7.1)

AMPHETAMINE SALTS 10 mg bid

Dispense in a tight, light-resistant container as defined in the USP. 

Cap: Orange opaque printed “P” in black ink and Body: Orange opaque printed “842” in black ink